EP300 promotes macrophage M2 polarization in diffuse large B-cell lymphoma through the NF-κB/CXCR4 axis
This study demonstrates that EP300 overexpression in diffuse large B-cell lymphoma drives macrophage M2 polarization and tumor progression via an EP300–NF-κB–CXCR4 axis, identifying EP300 as a promising therapeutic target for high-EP300 DLBCL.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer is rarely just a problem of the tumor cells themselves. Inside a tumor, there is a bustling neighborhood of other cells, including immune cells that are supposed to protect the body. Sometimes, the cancer tricks these immune defenders into switching sides, turning them from soldiers that attack the disease into helpers that feed it. This is particularly true for a common and aggressive type of blood cancer called diffuse large B-cell lymphoma. In these patients, the cancer cells often recruit a specific type of immune cell known as a macrophage and convince it to become "M2." Instead of fighting the cancer, these M2 macrophages build a shield around the tumor, helping it grow and resist treatment. Understanding how the cancer pulls this switch is the key to finding new ways to stop it.
Researchers at the Xinjiang Medical University Affiliated Tumor Hospital have uncovered a specific chain of events that allows these lymphoma cells to manipulate their surroundings. They focused on a protein called EP300, which acts like a master switch inside the cell's nucleus, turning other genes on or off. In healthy cells, this protein helps manage normal functions, but in many cases of this lymphoma, the cancer cells produce far too much of it. The team discovered that this excess EP300 is not just a bystander; it is a driver of the disease. By studying tissue samples from 154 patients, they found that those with high levels of EP300 had significantly shorter survival times compared to those with lower levels. The protein was also much more common in cancerous tissue than in benign, non-cancerous lymph node swelling.
To understand exactly what this protein was doing, the scientists turned to laboratory models. They used a precise genetic tool to remove the EP300 gene from lymphoma cells grown in a dish. Without this protein, the cancer cells stopped growing as fast and began to die off naturally. But the most revealing part of the experiment happened when they looked at what the cancer cells were sending out into their environment. The researchers found that when EP300 was present, the cancer cells pumped out a steady stream of chemical signals, including specific proteins that act as invitations for macrophages. When the scientists removed EP300, the production of these signals dropped dramatically. The cancer cells essentially stopped sending the "come here" messages that usually recruit and reprogram the immune system.
The study traced the mechanism behind this change to a well-known signaling pathway inside the cell, often called the NF-κB pathway. The researchers showed that EP300 normally helps keep this pathway active, which in turn turns on the genes for the chemical signals that attract macrophages. One of the most important signals identified was a protein called CXCR4, which sits on the surface of cells and helps them sense their environment. When EP300 was removed, the levels of CXCR4 fell, and the cancer cells lost their ability to influence nearby immune cells.
To see if this change actually affected the immune cells, the team took the liquid surrounding the cancer cells—known as conditioned medium—and applied it to macrophages in a separate dish. When the macrophages were exposed to fluid from normal cancer cells, they adopted the helpful, tumor-supporting M2 shape. However, when the macrophages were exposed to fluid from the cancer cells that had been stripped of EP300, they changed their behavior. They shifted toward a different state, one that is more likely to fight the tumor rather than help it. This confirmed that the cancer cells were using EP300 to secrete chemicals that actively reprogrammed the immune system.
The findings were not limited to the lab. When the researchers looked back at the tissue samples from the 154 patients, they found a clear pattern: tumors with high levels of EP300 were packed with the very same M2 macrophages that the lab experiments had identified. The more EP300 the cancer cells had, the more of these helpful-to-the-tumor immune cells were found inside the tumor. This connection held true even when accounting for other factors like the patient's age or the stage of the cancer, suggesting that EP300 is an independent marker for a worse outcome.
The researchers also tested this in living animals. They injected mice with lymphoma cells that either had EP300 or lacked it. The tumors formed by the cells without EP300 grew much slower and were significantly smaller at the end of the study. This proved that removing the protein does not just change the cells in a dish; it stops the tumor from taking hold in a living body.
While the study provides a clear picture of how EP300 drives the cancer's ability to hide from the immune system, the authors note that the full story is still being written. They observed that the effect was strongest in one specific type of lymphoma cell line, suggesting that the exact details might vary slightly between different patients. They also point out that while they have identified the chain of events, further work is needed to confirm every single step in the process. However, the evidence is strong enough to suggest that EP300 is a critical piece of the puzzle. By identifying this protein as a central hub that controls the cancer's relationship with the immune system, the study points toward a new strategy for treatment. If doctors could block EP300, they might be able to stop the cancer from recruiting its immune helpers, potentially turning the body's own defenses back against the tumor.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.